1. Home
  2. NEN vs GNFT Comparison

NEN vs GNFT Comparison

Compare NEN & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEN
  • GNFT
  • Stock Information
  • Founded
  • NEN 1977
  • GNFT 1999
  • Country
  • NEN United States
  • GNFT France
  • Employees
  • NEN N/A
  • GNFT N/A
  • Industry
  • NEN Building operators
  • GNFT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NEN Real Estate
  • GNFT Health Care
  • Exchange
  • NEN Nasdaq
  • GNFT Nasdaq
  • Market Cap
  • NEN 279.4M
  • GNFT 296.4M
  • IPO Year
  • NEN N/A
  • GNFT 2019
  • Fundamental
  • Price
  • NEN $82.49
  • GNFT $4.31
  • Analyst Decision
  • NEN
  • GNFT Strong Buy
  • Analyst Count
  • NEN 0
  • GNFT 1
  • Target Price
  • NEN N/A
  • GNFT $13.00
  • AVG Volume (30 Days)
  • NEN 417.0
  • GNFT 5.6K
  • Earning Date
  • NEN 01-01-0001
  • GNFT 09-19-2024
  • Dividend Yield
  • NEN 1.94%
  • GNFT N/A
  • EPS Growth
  • NEN 67.91
  • GNFT N/A
  • EPS
  • NEN 3.91
  • GNFT 0.47
  • Revenue
  • NEN $81,169,352.00
  • GNFT $86,225,222.00
  • Revenue This Year
  • NEN N/A
  • GNFT $155.44
  • Revenue Next Year
  • NEN N/A
  • GNFT N/A
  • P/E Ratio
  • NEN $21.12
  • GNFT $8.81
  • Revenue Growth
  • NEN 10.81
  • GNFT 175.45
  • 52 Week Low
  • NEN $66.25
  • GNFT $3.08
  • 52 Week High
  • NEN $84.00
  • GNFT $6.42
  • Technical
  • Relative Strength Index (RSI)
  • NEN 56.34
  • GNFT 27.46
  • Support Level
  • NEN $79.55
  • GNFT $4.26
  • Resistance Level
  • NEN $82.48
  • GNFT $5.81
  • Average True Range (ATR)
  • NEN 0.77
  • GNFT 0.18
  • MACD
  • NEN 0.10
  • GNFT -0.17
  • Stochastic Oscillator
  • NEN 99.83
  • GNFT 2.66

About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.

About GNFT GENFIT S.A.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Share on Social Networks: